FGFR3 and cancer: With the striking results from the drugs targeting mutant FGF/FGFR in various cancer, non-selective FGF/FGFR inhibitors have been approved for cancer treatment, especially for tumors harboring aberrant FGFR2 or FGFR3 activations 11, 13.